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Background: Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) is a sensorimotor disorder that causes
patients to experience overwhelming and distressing sensations in the legs compelling the patient to move their
legs to provide relief. The purpose of this study was to determine if biomarkers in the cerebrospinal fluid can
distinguish RLS/WED patients from neurological controls.
Methods: We obtained CSF samples by lumbar puncture from 5 early-onset RLS/WED patients and 5 controls. We
performed 2-dimensional difference in-gel electrophoresis (2D-DIGE). Proteins that were significantly altered were
identified by Student’s t-test. Protein spots that were differentially expressed (p ≤ 0.05, Av. Ratio ≥ 2.0) between
RLS/WED and control CSF samples were identified using MALDI-TOF-MS. Statistical analyses of the validation
immunoblot assays were performed using Student’s t-test.
Results: In this discovery study we identified 6 candidate CSF protein markers for early-onset RLS/WED. Four
proteins (Cystatin C, Lipocalin-type Prostaglandin D2 Synthase, Vitamin D binding Protein, and β-Hemoglobin) were
increased and 2 proteins (Apolipoprotein A1 and α-1-acid Glycoprotein) were decreased in RLS/WED patients.
Conclusions: Our results reveal a protein profile in the RLS/WED CSF that is consistent with clinical findings of
disruptive sleep, cardiovascular dysfunction and painful symptoms. Moreover, protein profiles are consistent with
neuropathological findings of activation of hypoxia inducible factor (HIF) pathways and alterations in dopaminergic
systems. These data indicate the CSF of RLS/WED patients may provide information relevant to biological basis for
RLS/WED, treatment strategies and potential new treatment targets.
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Restless Legs Syndrome/Willis-Ekbom Disease (RLS/
WED) is a sensorimotor disorder that affects between
5-10% of the population [1]. Patients who suffer with
RLS/WED experience an overwhelming and distressing
sensation that forces them to move their legs [2]. Those
with moderate to severe symptoms report significant
disability, chronically reduced sleep times, 20% reduction
in their work productivity, diminished quality of life, and
increased depression and anxiety [3]. RLS/WED has also* Correspondence: smp11@psu.edu
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reproduction in any medium, provided the orbeen identified as a risk factor for cardiovascular disease
[4-7]. RLS/WED prevalence increases with age and it
affects women twice as frequently as men.
Iron dysregulation in the pathogenesis of RLS/WED is
supported by a substantial volume of research including
several studies reporting decreased ferritin in cerebro-
spinal fluid (CSF) and decreased brain iron particularly
in the substantia nigra using MRI, ultrasound imaging
and brain autopsy analysis [8]. A number of studies to
date support the concept of diminished brain iron in
RLS/WED, thus providing the basis for the hypothesis
that RLS/WED occurs as a result of low brain iron con-
tent [8-10]. We still do not understand, however, the full
consequences that low brain iron may have on neuralLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proteomic analyses in order identify neural systems and
pathways that are altered in those suffering with RLS/
WED and possibly identify novel avenues for potential
therapeutic intervention.
CSF was utilized for this biomarker study because it is
most likely to reflect changes in CNS metabolic status
due to its proximity to the brain. An advantage of CSF
as the biological fluid for proteomic analyses over blood
is that the CSF is sequestered behind both the blood–
brain and brain-CSF barriers. This isolation permits the
identification of biomarkers that are specific to CNS
disease processes. Hence, our goal for this study was to
identify CSF biomarkers for RLS/WED using two-
dimensional difference-in-gel electrophoresis (2D-DIGE)
together with tandem Mass Spectrometric (MS) analysis.
To further validate the identified biomarkers, we used
immunoblot analyses to quantify differences in protein
levels between early-onset RLS/WED and age- and
gender-matched control subjects. In this study, we iden-
tify six proteins whose levels are altered in early-onset
RLS/WED subjects.
Methods
Patient demographics and CSF collection
The study was approved by DongSan Medical Center
Institutional Review Board in Taegu, South Korea where
subjects were recruited and CSF was collected. The
two-dimensional Difference-In-Gel Electrophoresis ana-
lyses were performed at Penn State Hershey College of
Medicine. The diagnosis of RLS/WED was made by a
board certified Korean neurologist with expertise in
RLS/WED diagnosis (YWC). The diagnosis was based
on diagnostic standards set by the NIH workshop on
RLS/WED [2] and was made during a face-to-face inter-
view utilizing questionnaire from the validated Korean-
language version [11] of the validated John Hopkins
Telephone diagnostic questionnaire [12] in order to ex-
clude RLS mimics and peripheral neuropathy. All RLS/
WED subjects in this study were diagnosed with primary
RLS (i.e., no subjects had RLS due to other causes such
as peripheral neuropathy, neurodegenerative disorders,
multiple sclerosis, drug use, and/or chronic renal fail-
ure). All of the RLS/WED subjects were required to haveTable 1 RLS/WED patient demographics
Subject number Onset age (years) Family his
RLS/WED 1 27 negative
RLS/WED 2 30 negative
RLS/WED 3 34 negative
RLS/WED 4 20 negative
RLS/WED 5 35 negativethe onset of symptoms prior to the age of 35. All of the
RLS/WED were asked about a family history of RLS but
having a positive family history of RLS was not required
for inclusion and no family history of RLS/WED was
reported by any study participants (Table 1). Control
subjects were matched for age and gender and the
demographics are shown in Table 2. The controls lacked
any major medical, psychiatric or neurological disorders
and had to answer “no” on the first two questions of the
RLS/WED Diagnostic Questionnaire [11,12]. Both RLS/
WED and control subject participants were screened for
obstructive sleep apnea through sleep questionnaires. In
addition, all subjects (both RLS/WED and controls) had
to meet the following criteria: 1) no dopaminergic, anti-
convulsant, or opioid medication use within the previous
6 weeks; 2) no sedating anti-histamine or short-acting
sedatives (GABA-active) medication use within the pre-
vious 4 weeks; 3) no use of psychiatric medication in-
cluding anti-depressants or dopaminergic medication;
although hypnotics were not excluded as standard hyp-
notics have little effect on iron or dopamine levels; 4) no
evidence of abnormal liver function (as measured by
elevated serum glutamic oxaloacetic transaminase
(SGOT), elevated serum glutamic-pyruvic transaminase
(SGPT), elevated bilirubin, or elevated alkaline phos-
phatase values); 5) no evidence of an abnormal complete
blood count (CBC); 6) no evidence of an abnormal
blood urea nitrogen (BUN) or creatinine value; 6) no
evidence of low hemoglobin (<11); 7) no history of blood
transfusion or donation within the last 6 months; 7)
BMI <35; and 8) no reported use of iron or other metal
supplements within the 6 weeks prior to the study.
After written informed consent was obtained from the
research subjects, approximately 10 mL of CSF was
obtained via lumbar puncture with a 25-gauge needle
and placed immediately on ice. CSF specimens were
spun at low speed in a refrigerated centrifuge to remove
any cellular contamination, aliquoted, and stored at −80°
C within 1 h. All samples were collected between 9:30
AM and 11:00 AM. The CSF samples were precipitated
with trichloroacetic acid/acetone following storage at−
80°C and the protein pellets were resuspended in 10 μL
of DIGE labeling buffer (7 M urea, 2 M thiourea, 4%

















Mean ± SD Mean ± SD p-value
58.00 ± 12.10 58.80 ± 7.66 0.904
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tein levels were quantified using the 2D Quant-Kit
(GE Healthcare, Uppsala, Sweden).
Materials
Isoelectric pH gradient (IPG) strips, urea, 3-[(3-
cholamidopropyl)-dimethylammonio]-1-propanesulfonate
(CHAPS), dithiothreitol (DTT), Pharmalyte pH 3–11,
acrylamide, ammonium persulfate, TEMED, glycine,
methylene bisacrylamide, TRIS, thiourea, and 2-D Quant
Kit (PlusOne or Ettan™ sample preparation kits and re-
agents) were obtained from GE Healthcare (Piscataway,
NJ, USA). ReadyPrep 2D-Clean-up Kit was obtained from
Bio-Rad (Hercules, CA, USA). Iodoacetamide and mineral
oil were obtained from Sigma (St. Louis, MO). SDS was
obtained from USB (Cleveland, OH, USA). Methanol and
glacial acetic acid were purchased from Fisher Scientific
(Fair Lawn, NJ, USA).
Two-dimensional difference-in-gel electrophoresis (2-D
DIGE) labeling
Each of the dry CyDyes (GE Healthcare) was recon-
stituted and 50 μg of total protein was labeled with each
diluted CyDye solution as described in the manufac-
turer’s protocol.
2-D PAGE analysis
CSF containing 150 μg of labeled protein was added to
an IPG strip. Strips were rehydrated for 20 h followed by
isoelectric focusing for 27 h. The following gradient pro-
gram was used – step 1: 0.01 h, 150 V, 2 mA, 5 W; step
2: 2.00 h, 150 V, 2 mA, 5 W; step 3: 6.00 h, 500 V, 2 mA,
5 W; step 4: 5.00 h, 3500 V, 2 mA, 5 W; step 5: 9.20 h,
3500 V, 2 mA, 5 W; step 6: 5.00 h, 50 V, 2 mA, 5 W.
SDS-PAGE was carried out in 12.5% of acrylamide. Fol-
lowing the focusing step, the proteins on the strip were
reduced and alkylated with gentle shaking in two subse-
quent steps for 30 min each in 10 ml equilibration buffer
(6 M Urea, 75 mM Tris–HCl pH 8.8, 29.3% glycerol, 2%
SDS, 0.002% bromophenol blue) containing 100 mg
DTT and 250 mg iodoacetamide in the second step.Strips were removed from equilibration solution, blotted,
and placed on a 1-mm thick 25.5 × 20.5 cm 12.5% acryl-
amide non-gradient SDS gel. The strips were sealed with
1% agarose, 125 mM Tris–HCl at pH=6.8, 1% SDS. Pro-
teins were separated on the gels using 600 V, 400 mA,
100 W for 4 h at 10°C. Analytical gels were imaged im-
mediately after separation, while the preparative gels
were fixed with 7.5% acetic acid/10% methanol overnight
and stained with Coomassie Blue R-350. The images
from analytical gels were collected as described previ-
ously [13]. Intra-gel spot detection, inter-gel matching
and normalization of spot intensities were performed
using the Differential In-gel Analysis (DIA) mode and
Biological Variation Analysis (BVA) mode of DeCyder
2D software (GE Healthcare, Munich, Germany), re-
spectively. In-Gel Trypsin Digestion of Proteins and
Mass Spectroscopic analyses for these experiments were
performed as described previously [13].
Immunoblotting analysis
Each of the proteins identified by 2-D DIGE analyses was
confirmed by immunoblot analyses. Protein concentration
was determined and immunoblot analyses were performed
as described previously [14]. An aliquot of total CSF
containing 1-3 μg from each of the subject participants
was used for the validation analyses. Mouse monoclonal
anti-apolipoprotein-A1, anti- α-1-acid glycoprotein, anti-
vitamin D binding protein, anti-cystatin C, and anti-β
-hemoglobin and rabbit polyclonal anti-prostaglandin D2
synthase were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). In addition, H-ferritin was quanti-
fied using immunoblot analyses. One μg of total protein
was used for the analysis and a custom rabbit polyclonal
H-ferritin antibody from Covance Biotechnology (Denver,
PA, USA) was used as the primary antibody. All immuno-
blot analyses were run in triplicate.
The immunoblots were quantified using densitometric
analysis. Chemiluminescent detection was performed
using either anti-mouse or anti-rabbit IgG ECL HRP-
conjugated secondary antibodies (GE Healthcare).
FujiFilm imaging system was used for detection, and
densitometric analysis was performed with Multiguage
software version 3.0.
Statistical analyses
The Extended Data Analysis tool (EDA) in the DeCyder
2D software package was used for the statistical analysis
of the 2D-DIGE experiments. Proteins that were signifi-
cantly altered were identified by Student’s t-test. Protein
spots that were differentially expressed (p ≤ 0.05, Av.
Ratio ≥ 2.0) between RLS/WED and control CSF sam-
ples were identified using MALDI-TOF-MS.
Statistical analyses of the validation immunoblot assays
were performed using Student’s t-test.
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CSF protein profile
CSF was obtained from 5 female RLS/WED patients
(mean age ±SD 58.0±12.1 years old) and 5 female
age-matched controls (mean age ± SD 58.8±7.66 years
old) (Table 2). The mean RLS/WED Severity score on
the International RLS Study Group (IRLSSG) scale was
31.6±4.15. Analysis of the protein expression using
DeCyder-DIA software provided 3-D simulation of the
protein spots, allowing an objective view for comparison
of spot intensity between the different gels. Reproduci-
bility and consistency in our results was enhanced by
performing all analyses at least in duplicate and analyz-
ing the duplicate samples. Approximately 663 protein
spots were identified when 20,000 pixels were used as
the filter limit in each group of samples. A composite
3-D image is shown for each group in a representative
area of the gel (Figure 1). The data from the gels were
reviewed by an investigator blinded in regard to the
sample identification. Of the 663 spots in the gel that
were observed, 6 met the pre-experiment criterion of
having at least a two-fold difference in intensity (p ≤
0.05, Av. Ratio ≥ 2.0). These protein spots were chosen
for identification by MALDI-TOF. Of the six proteins
selected (Table 3), four were increased and two were
decreased in the RLS/WED subjects.
Immunoblot analyses
Immunoblot validation was performed on all of the can-
didate proteins. Cystatin C was able to be validated with
immunoblot analyses (Figure 2) and was elevated in the
RLS/WED group (p < 0.05). In addition, because it had
been reported that the expression of proteins involved inFigure 1 Representative 2D-DIGE analysis of RLS/WED versus Control C
CSF from RLS/WED and Control subjects. Differentially expressed proteins a
be identified by MS/MS are listed in the legend.maintaining iron homeostasis in CSF were altered in
CSF in patients with RLS/WED, H-ferritin levels were
determined in the CSF using immunoblot analyses but
the differences did not reach statistical significance.
Discussion
Prior to this study, only specific iron-related proteins and
dopaminergic metabolites have been examined in the CSF
of RLS/WED patients [15,16]. Although the importance of
iron in the etiology of early-onset RLS/WED has been
established, our proteomic approach in this study permit-
ted identification of proteins that could prove valuable in
understanding pathways affected in RLS/WED and identi-
fying targets for treatment strategies.
In this discovery study, we have utilized a 2D-DIGE
coupled with tandem MS to identify 6 candidate CSF
protein markers for early-onset Restless Legs Syndrome
(RLS/WED); four proteins (Cystatin C, Lipocalin-type
Prostaglandin D2 Synthase, Vitamin D binding Protein,
and β-Hemoglobin) were increased and 2 proteins (Apo-
lipoprotein A1 and α-1-acid Glycoprotein) were de-
creased in RLS/WED patients compared to controls.
Cystatin C levels were increased in the CSF of early-
onset RLS/WED patients. Cystatin C is a cysteine pro-
teinase inhibitor that has multiple functions in vivo. It is
known to inhibit both endogenous and exogenous cyst-
eine peptidases, regulate the immune system, have anti-
bacterial and/or antiviral effects; and neuroprotective
effects during brain injury. Cystatin C has been de-
scribed previously as a biomarker of pain in lumbar disk
herniation, sciatica, and labor [17,18]. The level of
cystatin C observed in the CSF of patients with these
conditions was found to be dependent on the pain’sSF. This figure represents a single 2D-DIGE analysis performed on the
re encircled in red. Differentially expressed proteins that were able to
Table 3 CSF proteins showing at least a two-fold difference in expression between RLS/WED and control subjects
Identified protein Gi access no. Gene name Function Fold change MW pI
Proteins that are down-regulated-regulated in RLS/WED CSF
Apolipo protein A-I (precursor) 4557321 APOA1 Major protein component of
high density lipoprotein (HDL)
in plasma. Promotes cholesterol
efflux from tissues to the liver for excretion.
−1.97 30758.93 5.56
Alpha-1-acid glycoprotein 1 112877 AGP Reduces neutrophil phagocytosis
of bacteria, inhibits neutrophil migration
and superoxide production, reduces activated
platelet aggregation, and inhibits activated
lymphocytes proliferation.
−5.25 23724.84 4.93
Proteins that are up-regulated in RLS/WED CSF
vitamin D-binding protein (precursor) 181482 GC Binds vitamin D and its metabolites
and transports them to target tissues
2.32 54611.68 5.4
Prostaglandin D2 synthase 21kDa (brain) 55962673 PTGDS Neuromodulator and trophic factor
in the CNS. Involved in smooth muscle
contraction and relaxation; and inhibits
platelet aggregation.
2.18 23049.57 9.92
cystatin C 181387 CST3 Inhibitor of lysosomal proteinases and an
extracellular inhibitor of cysteine proteases
11.32 16047.18 9
β-Hemoglobin 183830 HBB most common form of hemoglobin
in adult humans
4.53 16086.3 6.75
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cystatin C in the CSF from RLS/WED patients is consist-
ent with multiple reports of pain associated with RLS/
WED symptoms and increased temporal summation to
heat pulses in RLS/WED patients suggesting that RLS/
WED is associated with amplified CNS pain processing
[19,20]. Also, RLS/WED has significant comorbitity with
a number of pain conditions such as fibromyalgia [21]
and headache [22]. The finding of elevated cystatin C in
the CSF of RLS/WED subjects may provide an objectiveFigure 2 Immunoblot quantification for cystatin C in CSF of RLS/
WED and control subjects. This figure demonstrates that RLS/WED
CSF contains higher Cystatin C levels compared to control subjects.
This data is compiled from the CSF from 5 RLS/WED and 5 control
patients and each sample was analyzed in triplicate. Single line
reflects the median value and the asterisk (*) reflect statistical
significance (p <0.05) as determined by an unpaired t-test analysis.measure of the pain associated with RLS/WED in some
of the patients. Also cystatin C has been reported to be
elevated in response to inflammation; therefore, there is
the potential that immune system activation may be oc-
curring in the CNS of patients with RLS/WED. A recent
review by Weinstock et al. [23] suggests that some con-
ditions that are associated with RLS/WED have an in-
flammatory/immune component and that inflammation
may be responsible for the CNS iron deficiency.
In this study, we found increased levels of lipocalin-
type prostaglandin D2 synthase (L-PGDS) in RLS/WED
CSF. L-PGDS is the most abundant protein in the CSF
and serves two roles: 1) synthesis of prostaglandin D2
(PGD2) from prostaglandin H2 (PGH2); and 2) binding
and transporting small lipophilic molecules. L-PGDS
alterations have been reported in a number of sleep dis-
orders including narcolepsy and obstructive sleep apnea
with and without daytime sleepiness [24-26] and thus its
increase is relevant to sleep disruptions in RLS/WED.
We have reported that PGDS is decreased in CSF of
monkeys that were iron deficient [13]. Furthermore, the
increase in PGDS in RLS/WED CSF is inconsistent with
the reports of decreased brain iron status in RLS/WED
[14]. We suggest that the increase in PGDS that was ob-
served in RLS/WED patients could be part of a compen-
satory mechanism. It has been reported that L-PGDS is
upregulated in the brains of subjects with hypoxic-
ischemic encephalopathy (HIE) [25]. Also, it has been
demonstrated in a mouse model of HIE that L-PGDS
and HIF-1α expression are co-localized and it was
implied that L-PGDS may protect neurons from hypo-
xic insult by local secretion of PGD2. We could
Patton et al. Fluids and Barriers of the CNS 2013, 10:20 Page 6 of 8
http://www.fluidsbarrierscns.com/content/10/1/20hypothesize, therefore, that the increased L-PGDS in
RLS/WED may be a result of hypoxia pathway activation
[25]. This hypothesis is further supported by our recent
finding of HIF pathway activation in the brains and mi-
crovasculature of RLS/WED subjects [27].
In this study, we report elevated vitamin D binding
protein in the CSF of RLS/WED subjects. Vitamin D
binding protein (VDP) is noted for specifically binding
and transporting a number of sterols including vitamin
D metabolites to target cells, however, it has been also
been shown to be a scavenger of toxins that are released
due to cellular injury or death [28] and a modulator of
the immune response [29]. Alterations in cerebrospinal
fluid levels of VDP have been linked primarily to
neurodegenerative diseases, such as multiple sclerosis,
Parkinson’s disease, and trauma [17,30,31]. Vitamin D
also has important ties to the pathways that have been
identified in the etiology of RLS/WED. Vitamin D defi-
ciency has been linked to altered dopamine concentra-
tions in the cortex [32], and blood and tissue iron
content has been reported to increase following vitamin
D supplementation [33]. Balaban et al. have reported de-
creased serum 25-hydroxyvitamin D levels in female
RLS/WED subject and have postulated that the CNS
iron deficiency that occurs in RLS/WED may induce
alterations in the dopaminergic pathway via a vitamin
D-mediated pathway [34]. Because of the tie between
iron, dopamine and vitamin D, it is tempting to propose
that elevated VDP that we observed in this study could
be reflective of the alterations in the iron/dopamine
pathway. One could also hypothesize that the elevation
of VDP could also be reflective of activation of inflam-
matory/immune cascades in the CNS of RLS/WED sub-
jects as further supported by the alterations of cystatin C
and alpha-1 acid glycoprotein levels in RLS/WED CSF.
Beta-Hemoglobin was found to be increased in RLS/
WED CSF. β-Hemoglobin is a major component of adult
hemoglobin and normally is not present in the CSF. As
such, the presence of β-Hemoglobin in the CSF is often
considered to be indicative of blood contamination.
While, obtaining a CSF tap with no blood contamination
is extremely difficult, we have examined the CSF
for frank signs of blood to rule out contamination.
β-Hemoglobin is known to transport oxygen in the
blood, however, it has also been reported to be import-
ant in dopamine regulation in the brain [35]. Biagioli
and colleagues have reported that overexpression of
Hbb-b1 and Hba-a1 (the genes encoding Hemoglobin
β and Hemoglobin α) in dopaminergic cell lines alters
transcription of genes related to iron metabolism, oxy-
gen homeostasis, oxidative phosphorylation, and nitric
oxide synthesis [35]. Because evidence exists for the
disruption of both the dopaminergic and oxygen homeo-
static systems in RLS [27,36-38], it is tempting tosuggest the finding of increased β-hemoglobin in the
RLS/WED CSF may reflect a more chronic condition in
RLS/WED and perhaps may point to a mechanistic ex-
planation for the altered iron, dopamine and oxygen
protein profiles that are observed in RLS/WED.
Apolipoprotein A1 was found to be decreased in the
CSF of patients with RLS/WED. Apolipoprotein A1 is
the primary protein constituent of high density lipopro-
teins (HDL). Although the role of Apolipoprotein A1 in
the CNS is not completely understood, it is thought to
be important for transport of lipids into the brain [39].
To date, no association has been reported between
Apo-A1 and RLS/WED, however, recent studies [40,41]
have described a higher prevalence of hypercholesterol-
emia in RLS/WED subjects. Decreased serum Apo-A1
levels have been linked to increased incidence of cardio-
vascular disease [42] which, if the decrease in Apo-A1 that
was observed in RLS/WED CSF was reflective of a global
Apo-A1 level, this could be related to the increased risk
for cardiovascular disease in RLS/WED [4-7].
Alpha-1-acid glycoprotein levels were decreased in the
CSF from RLS/WED patients. Alpha-1-acid glycoprotein
(AGP) is synthesized primarily in the liver, but also is re-
portedly synthesized in the endothelial cells of the blood–
brain-barrier. Alpha-1-acid glycoprotein (AGP) is an acute
phase reactant that is involved in the inflammation
cascade and is thought to provide immediate and effective
response to inflammatory damage prior to successive pro-
tective mechanisms [43]. Their protective functions seem
to result mainly from iron sequestration [44,45]. Our find-
ing of decreased AGP in the CSF of RLS/WED subjects is
reflective of decreased iron content in the CNS and pro-
vides further support for altered iron homeostasis in the
brains of RLS/WED patients [14,46,47].
Conclusion
Our results reveal a protein profile in the RLS/WED
CSF that is consistent with iron deficiency, dopamine
dysregulation and inflammation. The APO-A1 finding
may be of relevance outside of CNS given the recently
reported increased risk of cardiovascular disease in pa-
tients with RLS and cardiovascular dysfunction and re-
ports of painful symptoms. The profiles in the CSF are
also consistent with neuropathological findings of activa-
tion of HIF pathways and alterations in dopaminergic
systems. The data indicate that the CSF protein profile,
if confirmed in larger sample sizes, may provide support
for existing hypotheses about a biological basis for RLS/
WED which could prove clinically meaningful in evalu-
ating therapeutic strategies and identifying new targets.
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